Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro

Bioelectrochemistry. 2007 Nov;71(2):113-7. doi: 10.1016/j.bioelechem.2007.05.002. Epub 2007 Jun 2.

Abstract

Ruthenium complex NAMI-A [ImH][trans-RuCl(4)(DMSO-S)Im] (Im = imidazole) is a potential chemotherapeutic drug in cancer treatment. Electroporation can be used to facilitate delivery of NAMI-A into cells. Suspension of B16F1 tumour cells from mouse melanoma in NAMI-A solution was exposed to a train of electric pulses. The effect of NAMI-A was determined by examining cell viability in clonogenic test. Our results show that electroporation increases the otherwise scarce in vitro effects of NAMI-A, i.e. reduces cell viability. At the conditions chosen for experiments 90% of cells survived in the presence of 1 microM NAMI-A, whereas in a combined treatment with 1 microM NAMI-A and electroporation only about 10% of cells survived.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents / toxicity
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Dimethyl Sulfoxide / analogs & derivatives*
  • Dimethyl Sulfoxide / therapeutic use
  • Dimethyl Sulfoxide / toxicity
  • Electrochemotherapy*
  • Electroporation
  • Melanoma, Experimental / drug therapy*
  • Melanoma, Experimental / pathology*
  • Mice
  • Neoplasm Metastasis / drug therapy
  • Organometallic Compounds / therapeutic use*
  • Organometallic Compounds / toxicity
  • Ruthenium Compounds

Substances

  • Antineoplastic Agents
  • Organometallic Compounds
  • Ruthenium Compounds
  • imidazolium-bis(imidazole)dimethylsulfoxideimidazotetrachlororuthenate(III)
  • Dimethyl Sulfoxide